ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5.
Nature. 2021.
PMID: 33953400
Clinical Trial.